Amyloid-Beta Plaques

The failure of a more-than-decade-long trial in patients with early-onset Alzheimer’s deals yet another blow to a key treatment theory, observers say.

Amyloid-beta pathology may drive common behavioral changes in Alzheimer’s disease — before changes to memory and cognition are evident, investigators say.

Slowing gait speed may signal the onset of dementia up to nine years before cognitive decline becomes evident, investigators say. It’s also linked to Alzheimer’s-related brain changes.

The Medicare coverage proposal for these drugs is too restrictive, limiting potential benefits to a select few, the two congressmen argue in a letter sent Monday to HHS Secretary Xavier Becerra.

The risk of developing Alzheimer’s-associated brain plaques is only partly due to heredity, a new study of twins finds. The results suggest a role for modifiable factors as well, according to investigators.

The PrecivityAD blood test will lower barriers to participation in a new clinical trial that aims to prevent the symptoms of Alzheimer’s disease, researchers say.

The experimental Alzheimer’s drug gantenerumab is the “first and only” anti-amyloid antibody being investigated for subcutaneous administration and could potentially be given to patients...

The acting chief of the Food and Drug Administration has called for an investigation into the events leading up to the approval of Biogen’s brain plaque-clearing dementia drug aducanumab (Aduhelm).

The evidence convincingly shows that aducanumab (Aduhelm) removes beta amyloid — a hallmark of Alzheimer’s — from the brain, slowing the disease’s progression and giving patients and families much-needed...

If approved by the FDA, aducanumab would be the first-ever drug marketed to slow progression of the brain-wasting disease, according to its developer. But an advisory committee was unconvinced of the drug’s...